ReviewCancer gene therapy2026
The application of nanoparticle-mediated siRNA delivery systems in ovarian cancer.
Review in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ovarian cancer is one of the most common gynecological malignancies and has the highest mortality rate among gynecological cancers. Its difficulties in diagnosis, high mortality rate, high recurrence rate, and poor prognosis, have always been a major obstacle for researchers. Gene therapy, a revolutionary medical approach, can correct genetic defects to treat intractable diseases, enable personalized medicine, and boost medical research, thus holding great promise for reshaping healthcare. siRNA interference technology has become one of the key directions in drug research field due to its advantages of high efficiency, high specificity, and low toxicity. And the development of new targeted drugs using siRNA interference technology has attracted significant attention. However, siRNA needs to overcome the vascular barrier, achieve intracellular uptake and escape from lysosomes, while also avoiding degradation by nucleases. Fortunately, the emergence of nanomaterials has provided new insights and strategies for siRNA drug delivery. Herein, we review the current advances in nanoparticle-mediated siRNA delivery strategies, as well as the application of siRNA-loaded nanomaterials in the diagnosis and therapy of ovarian cancer.
Indexed as
Identifiers
41896658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.